CN115835867A - 苯并咪唑类衍生物、其制备方法及医药用途 - Google Patents

苯并咪唑类衍生物、其制备方法及医药用途 Download PDF

Info

Publication number
CN115835867A
CN115835867A CN202180049784.5A CN202180049784A CN115835867A CN 115835867 A CN115835867 A CN 115835867A CN 202180049784 A CN202180049784 A CN 202180049784A CN 115835867 A CN115835867 A CN 115835867A
Authority
CN
China
Prior art keywords
halogen
alkyl
optionally substituted
deuterium
hydrogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180049784.5A
Other languages
English (en)
Inventor
李文明
刘宁
刘彪
刘浩淼
余健
邹昊
祝伟
李正涛
张瑱
李云飞
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shanghai Tuojie Biomedical Technology Co ltd
Original Assignee
Shanghai Tuojie Biomedical Technology Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanghai Tuojie Biomedical Technology Co ltd filed Critical Shanghai Tuojie Biomedical Technology Co ltd
Publication of CN115835867A publication Critical patent/CN115835867A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D419/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms
    • C07D419/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

一种苯并咪唑类衍生物、其制备方法及医药用途。具体而言，一种通式(I)所示的苯并咪唑类衍生物、其制备方法及含有该衍生物的药物组合物以及其作为治疗剂的用途，特别是用于治疗与P2X3活性相关的疾病的用途。

Description

PCT国内申请，说明书已公开。

Claims (21)

  1. PCT国内申请，权利要求书已公开。
CN202180049784.5A 2020-08-13 2021-08-13 苯并咪唑类衍生物、其制备方法及医药用途 Pending CN115835867A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN2020108112674 2020-08-13
CN202010811267 2020-08-13
CN202110609305 2021-06-01
CN2021106093052 2021-06-01
PCT/CN2021/112386 WO2022033567A1 (zh) 2020-08-13 2021-08-13 苯并咪唑类衍生物、其制备方法及医药用途

Publications (1)

Publication Number Publication Date
CN115835867A true CN115835867A (zh) 2023-03-21

Family

ID=80247748

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180049784.5A Pending CN115835867A (zh) 2020-08-13 2021-08-13 苯并咪唑类衍生物、其制备方法及医药用途

Country Status (9)

Country Link
US (1) US20230250095A1 (zh)
EP (1) EP4198034A4 (zh)
JP (1) JP2023536986A (zh)
KR (1) KR20230051209A (zh)
CN (1) CN115835867A (zh)
BR (1) BR112023001924A2 (zh)
CA (1) CA3187092A1 (zh)
TW (1) TW202214619A (zh)
WO (1) WO2022033567A1 (zh)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202337452A (zh) * 2022-02-11 2023-10-01 大陸商江蘇恒瑞醫藥股份有限公司 P2x3受體拮抗劑的藥用鹽及其製備方法
TW202342468A (zh) * 2022-02-11 2023-11-01 大陸商江蘇恒瑞醫藥股份有限公司 P2x3受體拮抗劑的晶型及其製備方法

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102741245A (zh) * 2009-11-18 2012-10-17 阿斯利康(瑞典)有限公司 苯并咪唑化合物及其用途
WO2012158117A1 (en) * 2011-05-17 2012-11-22 Astrazeneca Ab Combination therapies for treating pain
CN105246888A (zh) * 2013-01-31 2016-01-13 尼奥迈德研究所 咪唑并吡啶化合物及其用途
CN108904507A (zh) * 2018-02-11 2018-11-30 赖英杰 P2x3受体调节剂苯并咪唑化合物在制备抗呼吸疾病药物中的应用
WO2019064079A2 (en) * 2017-09-18 2019-04-04 Bellus Health Cough Inc. SELECTIVE MODULATORS OF P2X3
WO2020135771A1 (zh) * 2018-12-29 2020-07-02 武汉朗来科技发展有限公司 杂环类化合物、中间体、其制备方法及应用

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100822530B1 (ko) 2004-03-05 2008-04-16 에프. 호프만-라 로슈 아게 Ｐ2ｘ3 및 ｐ2ｘ2/3 길항물질로서의 다이아미노피리미딘

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102741245A (zh) * 2009-11-18 2012-10-17 阿斯利康(瑞典)有限公司 苯并咪唑化合物及其用途
WO2012158117A1 (en) * 2011-05-17 2012-11-22 Astrazeneca Ab Combination therapies for treating pain
CN105246888A (zh) * 2013-01-31 2016-01-13 尼奥迈德研究所 咪唑并吡啶化合物及其用途
WO2019064079A2 (en) * 2017-09-18 2019-04-04 Bellus Health Cough Inc. SELECTIVE MODULATORS OF P2X3
CN108904507A (zh) * 2018-02-11 2018-11-30 赖英杰 P2x3受体调节剂苯并咪唑化合物在制备抗呼吸疾病药物中的应用
WO2020135771A1 (zh) * 2018-12-29 2020-07-02 武汉朗来科技发展有限公司 杂环类化合物、中间体、其制备方法及应用

Also Published As

Publication number Publication date
TW202214619A (zh) 2022-04-16
JP2023536986A (ja) 2023-08-30
EP4198034A4 (en) 2024-01-17
KR20230051209A (ko) 2023-04-17
WO2022033567A1 (zh) 2022-02-17
EP4198034A1 (en) 2023-06-21
BR112023001924A2 (pt) 2023-03-07
US20230250095A1 (en) 2023-08-10
CA3187092A1 (en) 2022-02-17

Similar Documents

Publication Publication Date Title
JP7339959B2 (ja) Ｎｌｒｐ３インフラマソーム調節剤としてのスルホニル尿素誘導体
CN113549068B (zh) 一类新型咪唑并吡啶化合物、其制备方法及其在医药上的应用
RU2605096C2 (ru) Пиразолохинолиновое производное
KR100633844B1 (ko) 2-시아노-4-플루오로피롤리딘 유도체 또는 그의 염
KR101033719B1 (ko) 아릴-아이속사졸-4-일-이미다조[1,5-ａ]피리딘 유도체
WO2022017339A1 (zh) 稠合哒嗪类衍生物、其制备方法及其在医药上的应用
TW294665B (zh)
TW201713665A (zh) 適用於治療與ｎｔｒｋ相關之病症的化合物及組合物
BRPI0708264A2 (pt) piperidinilpirrolidinas agonistas do receptor tipo 4 de melanocortina
BR112015007731B1 (pt) Composto, composição farmacêutica que o compreende e uso do mesmo
CN115835867A (zh) 苯并咪唑类衍生物、其制备方法及医药用途
CN115605479B (zh) 吡啶酮并嘧啶类衍生物、其制备方法及其在医药上的应用
CN115135656B (zh) 呋喃并吲唑衍生物
CN112673009B (zh) 被取代的三唑并喹喔啉衍生物
TW200835483A (en) Azaspiro derivatives
CN112771046B (zh) 其他被取代的三唑并喹喔啉衍生物
JP7530128B2 (ja) Ｆｇｆｒ阻害剤化合物及びその使用
TWI671299B (zh) 作為ｒｓｖ抗病毒化合物之螺脲化合物
CN106661032A (zh) 治疗或预防糖尿病、肥胖症和炎性肠病的1,3‑取代的2‑氨基吲哚衍生物及类似物
JP2023536891A (ja) 重症肺炎を治療するためのｊａｋ阻害剤化合物
CA3211437A1 (en) Furoindazole derivatives as gpr84 antagonists
TWI833193B (zh) 二唑化合物及含彼的藥學組成物
WO2022174765A1 (zh) 作为Wee-1抑制剂的稠环化合物
CN110272416A (zh) 吡唑并[3,4-c]吡啶-7-胺衍生物及其制备方法和应用
WO2022117062A1 (zh) 含有稠合三环的化合物及其医药用途

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40090713

Country of ref document: HK